Abstract
There are many established and proposed bio-molecular markers for cardiovascular disease, including vasoactive substances, substances related to inflammation and oxidative stress, and substances involved in tissue structure and remodeling. Among these substances, we focused on natriuretic peptides and adrenomedullin (AM) as clinically useful bio-molecular markers in this review. Three natriuretic peptides-atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP)-play various important roles in the cardiovascular system. ANP and BNP are released from the heart and exist primarily as circulating hormones. They participate in the regulation of blood pressure and fluid levels. Plasma levels of ANP and BNP are increased in various pathological conditions such as heart failure, myocardial infarction, and hypertension with cardiac hypertrophy. BNP is now essential as a biochemical marker in managing patients with cardiovascular disease. CNP is mainly produced in vascular endothelium. It contributes to smooth muscle relaxation and growth inhibition as a local hormone, but it is also synthesized in cardiac fibroblasts and inhibits fibroblast proliferation and myocyte growth. However, the significance of plasma CNP levels remains to be elucidated. AM is widely distributed in various organs and tissues, including the cardiovascular system. Not only it is a potent vasodilator peptide, but it also has protective effects against vascular and cardiac cell injury and excessive growth. Plasma AM levels are increased in several cardiovascular diseases, including hypertension, heart failure, myocardial infarction, and atherosclerotic disease, and AM appears to be a predictive and prognostic marker in the setting of cardiovascular disease. (Korean Circ J 2008;38:507-513)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have